Perosphere Technologies, a US-based medical technologies company, has entered an exclusive distribution agreement with M3 Medical, a part of Uniphar Medtech, to bring the Perosphere ClotChek point-of-care (PoC) coagulometer to Ireland.

This partnership marks Ireland as the first country to gain access to this diagnostic tool, designed to assist healthcare professionals in rapidly assessing coagulation status at the patient's bedside.

Perosphere ClotChek is a reagent-free diagnostic device that provides quick and accurate results within three to eight minutes, aiding in the management of patients requiring anticoagulants to prevent blood clots and stroke.

Perosphere chief operating officer Daryl Mootoo said: “We are excited to partner with M3 Medical based on the company’s longstanding expertise and demonstrated success in the medical device market to improve patient care.

“We trust in M3 Medical’s capabilities to bring Perosphere ClotChek to healthcare providers in Ireland and help us change the current standard of testing and care in anticoagulation management.”

The device's ease of use and rapid turnaround time are expected to enhance treatment decision-making in emergency and other medical settings. The product has already secured a CE Mark in the EU.

M3 Medical is a distributor specialising in interventional cardiology, radiology, neuroradiology, and vascular surgery.

Its established presence in the Irish and UK markets is anticipated to facilitate a successful rollout of the product.

Uniphar Medtech operates across 21 European markets and is headquartered in Ireland.

Commenting on the deal, M3 Medical business unit leader for Ireland Robbie Dolan said: “We recognise the value of Perosphere ClotChek, a unique coagulation testing device, especially in Ireland given the widespread use of anticoagulants and the unmet need for fast and complete coagulation diagnosis.

“We are proud to enter this exclusive agreement to help improve patient outcomes and reduce health system costs in Ireland.”